Business Context and Reporting Period
This Form 8-K is a current report filed by Virios Therapeutics, Inc. (not Dogwood Therapeutics, Inc.) on June 18, 2024. The filing details the results of the Company's Annual Meeting of Stockholders held on that date. The Company is incorporated in Delaware and its common stock trades on the Nasdaq Capital Market under the symbol "VIRI".
Key Financial Metrics
This filing is a corporate governance report regarding shareholder voting results. It does not provide financial data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The filing text does not provide a clear value for any financial performance indicators.
Material Changes and Voting Results
The filing reports the following material outcomes from the Annual Meeting:
- Attendance: Holders of 8,699,494 shares (45.17% of voting power) were present, constituting a quorum.
- Election of Directors: All six nominees were elected. Notable vote counts included:
- Richard Burch: 3,201,273 For, 205,492 Withheld.
- Abel De La Rosa, Ph.D.: 2,440,247 For, 966,518 Withheld.
- Richard J. Whitley, M.D.: 1,964,627 For, 1,442,138 Withheld.
- Auditor Ratification: The appointment of FORVIS, LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2024, was ratified with 8,347,686 votes For, 241,056 Against, and 110,752 Abstentions.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It is strictly a disclosure of shareholder voting results.
Investor Verification Checklist
- Verify the correct registrant name is Virios Therapeutics, Inc., as the input metadata incorrectly referenced Dogwood Therapeutics, Inc.
- Confirm the election results for the six directors, noting the significant number of withheld votes for Abel De La Rosa and Richard J. Whitley.
- Review the ratification of FORVIS, LLP as the independent auditor for the 2024 fiscal year.
- Check subsequent filings (e.g., 10-K or 10-Q) for actual financial performance data, as this 8-K contains none.